Which has preferable earnings & valuation, KLRA or DSGN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A N/A N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is KLRA or DSGN more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Design Therapeutics N/A -33.07% -31.29%

Which has better valuation & earnings, DSGN or IRON?

Disc Medicine is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Disc Medicine N/A N/A -$212.18M -$6.62 N/A

Is DSGN or IRON more profitable?

Design Therapeutics' return on equity of -33.07% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Disc Medicine N/A -36.94% -33.88%

Do analysts rate NNNN or DSGN?

Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 32.64%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Design Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Design Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has better valuation and earnings, NNNN or DSGN?

Anbio Biotechnology has higher revenue and earnings than Design Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 276.80 $6.40M N/A N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is NNNN or DSGN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A Design Therapeutics N/A -33.07% -31.29%

Is DSGN or ALMS more profitable?

Design Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Design Therapeutics' return on equity of -33.07% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Alumis -2,825.70% -88.79% -70.72%

Design Therapeutics (DSGN) Competitors

$12.44 +0.51 (+4.27%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$12.44 0.00 (0.00%)

As of 06/18/2026 04:54 PM Eastern

Compare

DSGN vs. TARS, KLRA, IRON, NNNN, and ALMS

Should you buy Design Therapeutics stock or one of its competitors? MarketBeat compares Design Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Design Therapeutics include Tarsus Pharmaceuticals (TARS), Kailera Therapeutics (KLRA), Disc Medicine (IRON), Anbio Biotechnology (NNNN), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

How does Design Therapeutics compare to Tarsus Pharmaceuticals?

Design Therapeutics (NASDAQ:DSGN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Tarsus Pharmaceuticals has higher revenue and earnings than Design Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Tarsus Pharmaceuticals	$451.36M	6.02	-$66.42M	-$1.14	N/A

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Design Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Design Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 32.64%. Tarsus Pharmaceuticals has a consensus price target of $90.67, indicating a potential upside of 43.55%. Given Tarsus Pharmaceuticals' higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

In the previous week, Tarsus Pharmaceuticals had 9 more articles in the media than Design Therapeutics. MarketBeat recorded 9 mentions for Tarsus Pharmaceuticals and 0 mentions for Design Therapeutics. Tarsus Pharmaceuticals' average media sentiment score of 0.30 beat Design Therapeutics' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Design Therapeutics	Neutral
Tarsus Pharmaceuticals	Neutral

Design Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

Summary

Tarsus Pharmaceuticals beats Design Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Design Therapeutics (NASDAQ:DSGN) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Kailera Therapeutics presently has a consensus target price of $42.75, suggesting a potential upside of 114.39%. Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 32.64%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Kailera Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

56.6% of Design Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kailera Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Design Therapeutics	N/A	-33.07%	-31.29%

In the previous week, Kailera Therapeutics had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 1 mentions for Kailera Therapeutics and 0 mentions for Design Therapeutics. Kailera Therapeutics' average media sentiment score of 0.68 beat Design Therapeutics' score of 0.00 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kailera Therapeutics	Positive
Design Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Summary

Kailera Therapeutics beats Design Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Design Therapeutics compare to Disc Medicine?

Design Therapeutics (NASDAQ:DSGN) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Disc Medicine is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Design Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

In the previous week, Disc Medicine had 21 more articles in the media than Design Therapeutics. MarketBeat recorded 21 mentions for Disc Medicine and 0 mentions for Design Therapeutics. Disc Medicine's average media sentiment score of 0.69 beat Design Therapeutics' score of 0.00 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
Design Therapeutics	Neutral
Disc Medicine	Positive

Design Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 32.64%. Disc Medicine has a consensus price target of $105.80, suggesting a potential upside of 49.46%. Given Disc Medicine's higher probable upside, analysts clearly believe Disc Medicine is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Design Therapeutics' return on equity of -33.07% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Disc Medicine	N/A	-36.94%	-33.88%

Summary

Design Therapeutics beats Disc Medicine on 9 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Design Therapeutics (NASDAQ:DSGN) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 32.64%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Design Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Anbio Biotechnology had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 1 mentions for Anbio Biotechnology and 0 mentions for Design Therapeutics. Anbio Biotechnology's average media sentiment score of 0.76 beat Design Therapeutics' score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
Design Therapeutics	Neutral

Anbio Biotechnology's return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Design Therapeutics	N/A	-33.07%	-31.29%

Anbio Biotechnology has higher revenue and earnings than Design Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	276.80	$6.40M	N/A	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

56.6% of Design Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Anbio Biotechnology has a beta of 4.38, indicating that its share price is 338% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Summary

Anbio Biotechnology beats Design Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Design Therapeutics compare to Alumis?

Design Therapeutics (NASDAQ:DSGN) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Design Therapeutics has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Alumis	$24.05M	124.10	-$243.32M	-$1.98	N/A

Design Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 32.64%. Alumis has a consensus price target of $40.30, suggesting a potential upside of 72.15%. Given Alumis' higher probable upside, analysts plainly believe Alumis is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

56.6% of Design Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 33.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alumis had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 1 mentions for Alumis and 0 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.00 equaled Alumis'average media sentiment score.

Company	Overall Sentiment
Design Therapeutics	Neutral
Alumis	Neutral

Design Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Design Therapeutics' return on equity of -33.07% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Alumis	-2,825.70%	-88.79%	-70.72%

Design Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Alumis has a beta of -0.56, meaning that its share price is 156% less volatile than the broader market.

Summary

Design Therapeutics beats Alumis on 9 of the 14 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DSGN vs. The Competition

Export

Metric	Design Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$745.11M	$3.41B	$6.66B	$12.38B
Dividend Yield	N/A	2.31%	2.68%	5.68%
P/E Ratio	-10.37	19.39	24.48	24.42
Price / Sales	N/A	319.38	577.04	128.85
Price / Cash	N/A	127.04	44.20	55.24
Price / Book	3.34	8.16	10.70	6.58
Net Income	-$69.79M	$23.89M	$3.57B	$337.29M
7 Day Performance	13.40%	2.54%	0.70%	0.60%
1 Month Performance	18.59%	5.98%	3.94%	5.00%
1 Year Performance	228.23%	53.51%	28.52%	31.05%

Design Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DSGN Design Therapeutics	2.1157 of 5 stars	$12.44 +4.3%	$16.50 +32.6%	+228.2%	$745.11M	N/A	N/A	40	Gap Up
TARS Tarsus Pharmaceuticals	3.0493 of 5 stars	$61.55 +3.2%	$90.67 +47.3%	+53.8%	$2.57B	$451.36M	N/A	50	News Coverage Insider Trade
KLRA Kailera Therapeutics	4.7765 of 5 stars	$19.64 -0.3%	$42.75 +117.7%	N/A	$2.54B	N/A	N/A	145
IRON Disc Medicine	2.4285 of 5 stars	$68.34 +3.9%	$105.30 +54.1%	+41.3%	$2.51B	N/A	N/A	30	Insider Trade
NNNN Anbio Biotechnology	1.3989 of 5 stars	$16.16 -6.2%	N/A	N/A	$2.48B	$8.65M	N/A	27	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DSGN) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Design Therapeutics (DSGN) Competitors

DSGN vs. TARS, KLRA, IRON, NNNN, and ALMS

How does Design Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Design Therapeutics compare to Kailera Therapeutics?

Summary

How does Design Therapeutics compare to Disc Medicine?

Summary

How does Design Therapeutics compare to Anbio Biotechnology?

Summary

How does Design Therapeutics compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Design Therapeutics (DSGN) Competitors

DSGN vs. TARS, KLRA, IRON, NNNN, and ALMS

How does Design Therapeutics compare to Tarsus Pharmaceuticals?

Which has better earnings and valuation, DSGN or TARS?

Do institutionals & insiders believe in DSGN or TARS?

Is DSGN or TARS more profitable?

Do analysts prefer DSGN or TARS?

Does the media favor DSGN or TARS?

Which has more volatility & risk, DSGN or TARS?

Summary

How does Design Therapeutics compare to Kailera Therapeutics?

Do analysts prefer KLRA or DSGN?

Do insiders & institutionals have more ownership in KLRA or DSGN?

Is KLRA or DSGN more profitable?

Does the media refer more to KLRA or DSGN?

Which has preferable earnings & valuation, KLRA or DSGN?

Summary

How does Design Therapeutics compare to Disc Medicine?

Which has better valuation & earnings, DSGN or IRON?

Do insiders and institutionals have more ownership in DSGN or IRON?

Which has more volatility and risk, DSGN or IRON?

Does the media prefer DSGN or IRON?

Do analysts prefer DSGN or IRON?

Is DSGN or IRON more profitable?

Summary

How does Design Therapeutics compare to Anbio Biotechnology?

Do analysts rate NNNN or DSGN?

Does the media refer more to NNNN or DSGN?

Is NNNN or DSGN more profitable?

Which has better valuation and earnings, NNNN or DSGN?

Do institutionals and insiders have more ownership in NNNN or DSGN?

Which has more risk and volatility, NNNN or DSGN?

Summary

How does Design Therapeutics compare to Alumis?

Which has better earnings and valuation, DSGN or ALMS?

Do analysts rate DSGN or ALMS?

Do insiders & institutionals have more ownership in DSGN or ALMS?

Does the media favor DSGN or ALMS?

Is DSGN or ALMS more profitable?

Which has more risk & volatility, DSGN or ALMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools